Abiopharma

Respiri Limited, a pioneering presence in the MedTech sector, is channeling innovation to alleviate the daily challenges faced by patients with chronic diseases and healthcare providers. Leveraging cutting-edge technology and medical device R&D, we extend care beyond clinic walls, equipping healthcare organisations with actionable patient data through our Remote Patient Monitoring (RPM) programs. With operations headquartered in Melbourne and offices in New York City and Miami, Respiri is strategically positioned to revolutionise chronic disease management globally but focussed on the US market where RPM services are recognised by Centres of Medicare and Medicaid Services (CMS) and eligible for Current Procedural Terminology (CPT) Code reimbursement. wheezo®, a world-first FDA-approved Class II medical device, stands as the sole WheezeRate detector capable of integration into RPM programs. Developed in Australia with the collaboration of international respiratory specialists, wheezo® utilizes innovative technology to analyse breath sounds, identifying wheeze, and enables users to log symptoms and triggers through the user-friendly respiri™ app

Additional info from OTC:
Respiri Limited, a pioneering presence in the MedTech sector, is channeling innovation to alleviate the daily challenges faced by patients with chronic diseases and healthcare providers. Leveraging cutting-edge technology and medical device R&D, we extend care beyond clinic walls, equipping healthcare organisations with actionable patient data through our Remote Patient Monitoring (RPM) programs. With operations headquartered in Melbourne and offices in New York City and Miami, Respiri is strategically positioned to revolutionise chronic disease management globally but focussed on the US market where RPM services are recognised by Centres of Medicare and Medicaid Services (CMS) and eligible for Current Procedural Terminology (CPT) Code reimbursement. wheezo®, a world-first FDA-approved Class II medical device, stands as the sole WheezeRate detector capable of integration into RPM programs. Developed in Australia with the collaboration of international respiratory specialists, wheezo® utilizes innovative technology to analyse breath sounds, identifying wheeze, and enables users to log symptoms and triggers through the user-friendly respiri™ app